Banai J
I. Belgyógyászati Klinika, Semmelweis Egyetem, Budapest.
Orv Hetil. 2000 May 28;141(22):1171-7.
Important progress has been made in recent years in the understanding of pathogenesis of Crohn's disease and ulcerative colitis, but the cause of IBD remains obscure, so curative therapy is still lacking. Current treatment strategies as sulphasalazine, mesalasine, glucocorticosteroids are mainly anti-inflammatory. In the past years the greatest advances have been characterised by the more widespread use of topically acting steroids, immunosuppressants and by the introduction of immunomodulatory agents as cytokines and anticytokines. The author summarises the standard therapy and new possibilities of medical treatment for IBD and suggests some algorythms for clinical practice.
近年来，在对克罗恩病和溃疡性结肠炎发病机制的理解方面取得了重要进展，但炎症性肠病（IBD）的病因仍不清楚，因此仍然缺乏根治性疗法。目前的治疗策略如柳氮磺胺吡啶、美沙拉嗪、糖皮质激素主要是抗炎的。在过去几年中，最大的进展表现为局部作用的类固醇、免疫抑制剂的更广泛使用以及作为细胞因子和抗细胞因子的免疫调节剂的引入。作者总结了IBD的标准治疗方法和新的药物治疗可能性，并提出了一些临床实践算法。
